LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Accueil・Liste d'Actions・Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc

Fermé

3.75 7.14

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.48

Max

3.76

Chiffres clés
By Trading Economics
Revenu	-136K -35M
BPA	-0.503
Employés	106
EBITDA	-619K -38M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+98.86% upside

Dividendes
By Acuity
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-34M 261M
Ouverture précédente	-3.39
Clôture précédente	3.75

Zentalis Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 juin 2026, 23:56 UTC

Mondelez International shares declined in after-market trading, continuing a trend of three consecutive lower closes amid rising US Treasury yields and mixed economic signals.

12 juin 2026, 23:56 UTC

ETF Constituents

Macro News

The U.S. government acquired a 10% stake in USA Rare Earth, boosting investor sentiment for gold-mining firms and contributing to GDX's after-market gains.

12 juin 2026, 23:51 UTC

Asia equity markets rise on U.S.-Iran peace deal optimism, while U.S. producer prices signal persistent inflation ahead of Fed's interest rate decision.

12 juin 2026, 23:51 UTC

Global equity markets rise on U.S.-Iran peace deal optimism, while U.S. consumer sentiment improves amid easing inflation concerns.

12 juin 2026, 23:51 UTC

European equity markets rise on optimism for U.S.-Iran peace deal, despite mixed economic data from the UK and easing inflation in Germany.

12 juin 2026, 23:51 UTC

US equity markets show mixed performance amid geopolitical developments and rising inflation concerns, with key economic indicators and Fed decisions on the horizon.

12 juin 2026, 23:51 UTC

U.S. Industrial Production MoM data set for June 15, 2026, forecasts a cautious optimism with a predicted increase of 0.2% following April's strong performance.

12 juin 2026, 23:51 UTC

United Airlines Holdings Inc. shares declined in after-market trading, despite initial gains, amid rising U.S. Treasury yields and mixed economic signals.

12 juin 2026, 23:46 UTC

Take-Two Interactive shares are higher in after-market trading, reflecting a modest gain since Friday's close, though still below the 20-day moving average.

12 juin 2026, 23:46 UTC

JD.Com Inc. shares are higher in after-market trading, despite no specific news. The stock is near the lower end of its one-month range.

12 juin 2026, 23:46 UTC

ETF Constituents

iShares MSCI South Korea ETF rises in after-hours trading, supported by top holding SKM. Global equity markets remain mixed amid geopolitical developments.

12 juin 2026, 23:41 UTC

Check Point Software Technologies shares are higher in after-market hours, with trading notably strong despite no specific news driving the movement.

12 juin 2026, 23:41 UTC

U.S. Retail Sales Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Geopolitical Tensions

12 juin 2026, 23:41 UTC

Cautious Optimism Surrounds Upcoming Canadian Housing Price Index Release Amidst Government Initiatives to Stabilize Market

12 juin 2026, 23:41 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Economic Uncertainties and Inflation Pressures

12 juin 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

12 juin 2026, 23:41 UTC

Fox Corp. shares are higher in after-market trading, reflecting a strong upward trajectory since Friday's close amid notable volatility.

12 juin 2026, 23:41 UTC

Baidu Inc. shares advanced in after-market trading, reaching a session high. The stock remains below its 20-day moving average amid rising bond yields.

12 juin 2026, 23:41 UTC

Correlated Moves

Bitcoin is trading lower on Friday, influenced by rising bond yields and a broader market decline in cryptocurrencies, including Ethereum.

12 juin 2026, 23:36 UTC

iShares Core U.S. Aggregate Bond ETF was roughly flat in after-market hours, maintaining stability near the upper end of its one-month trading range.

12 juin 2026, 23:36 UTC

Ross Stores Inc. shares declined in after-market trading, reflecting routine fluctuations. Broader market conditions were influenced by rising bond yields.

12 juin 2026, 23:36 UTC

The SPDR S&P Regional Banking ETF traded roughly flat in after-market hours, reflecting routine trading patterns amid mixed direction in broader U.S. stock indices.

12 juin 2026, 23:31 UTC

ETF Constituents

Macro News

Energy Select Sector SPDR Fund is lower in after-market hours, impacted by declines in Chevron and ExxonMobil, as broader market dynamics influence energy outlook.

12 juin 2026, 23:31 UTC

Market Awaits U.S. Building Permits Data Amid Mixed Sentiment and Economic Concerns Ahead of June 16 Release.

12 juin 2026, 23:31 UTC

Trip.com Group Ltd shares are higher in after-market trading, reaching a peak despite three consecutive lower daily finishes and being below its 20-day moving average.

12 juin 2026, 23:26 UTC

ETF Constituents

Macro News

The Industrial Select Sector SPDR Fund is trading higher in after-market hours, supported by positive industrial sector developments and gains among key holdings.

12 juin 2026, 23:26 UTC

ETF Constituents

The Materials Select Sector SPDR Fund is trading higher in after-market hours, supported by contributions from Freeport-McMoRan and Albemarle.

12 juin 2026, 23:22 UTC

Preliminary May 2026 Building Permits Data Set for Release Amid Cautious Optimism Following April's 5.8% Increase

12 juin 2026, 23:22 UTC

U.S. Export Prices Expected to Surge Amid Optimism from Geopolitical Developments and Recent Inflation Trends Ahead of June 16 Release

12 juin 2026, 23:22 UTC

Market Awaits May Housing Starts Data Amid Optimism for Real Estate Recovery and Government Initiatives on June 16, 2026.

Comparaison

Variation de prix

Zentalis Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

98.86% hausse

Prévisions sur 12 Mois

Moyen 7 USD 98.86%

Haut 10 USD

Bas 4 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

Achat

Maintien

Vente

Basé sur 7 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.